A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis

Abstract

Biophysical approaches reveal how a mutation in the constant light chain domain of a patient-derived antibody destabilizes the constant domain, prevents the dimerization of the light chain, and makes it more prone to proteolytic cleavage, unleashing the amyloidogenic potential of the isolated variable domain.